Related Experiment Video
Updated: Jul 17, 2026
Apparatus for Harvesting Tissue Microcolumns
Published on: October 25, 2018
Topical 10% Tranexamic Acid with and without Microneedling in the Treatment of Erythematotelangiectatic Rosacea: A
Refaat R Mohamed1, Leila Gallab Mahmoud Mohamed1, Mofreh Mansour1
1Drs. Refaat R. Mohamed, Mahmoud Mohamed, and Mansour are with the Department of Dermatology and Faculty of Medicine at Al-Azhar University in Assiut, Egypt.
Objective:
Erythematotelangiectatic rosacea (ETR) is recognized by flushing, persistent centrofacial erythema, and telangiectasia. Many lines of topical treatments have been used for ETR with variable outcomes. We aimed to evaluate the efficacy of 10% topical tranexamic acid (TXA) with and without microneedling in treating ETR.
Methods:
All patients received treatment on both sides of the face, the right side was treated with microneedling combined with 10% topical TXA, and the left side was treated with 10% topical TXA only. All patients received three sessions at two weeks intervals. The final evaluation was done three months after the last treatment session.
Results:
The study included 45 females. Their age ranged between 20 and 48 years. The duration of the disease ranged from two months to five years. Both sides of the face showed improvement after treatment. There was a clinically and dermoscopic significant improvement in the side treated with microneedling + TXA compared to the side of the face treated with TXA alone.
Limitations:
The small sample size and the lack of long-term follow-up.
Conclusion:
This study showed that TXA is an effective and safe treatment modality for ETR. Microneedling can enhance the delivery of TXA and lead to better outcomes regarding erythema and telangiectasia.
